Sector News

Endo announces change to senior management team

May 11, 2016
Life sciences

Endo International plc today announced that Brian Lortie, President, U.S. Branded Pharmaceuticals, has decided to step down from his position upon the appointment of a successor.

Mr. Lortie joined Endo in 2009 and led its U.S. Pharmaceuticals business with responsibility for all strategic, commercial and operational functions, including sales and marketing, strategy and portfolio development, commercial operations, managed markets, manufacturing, supply chain and quality. Endo has initiated a search with a leading executive recruitment firm to identify a successor for Mr. Lortie, who has agreed to remain with the Company until his replacement is hired.

“I would like to thank Brian for his important contributions to Endo. He led the U.S. Branded business through a time of great transformation – from a franchise largely focused on a small number of legacy pain products to a diversified business with growth drivers across multiple therapeutic areas including pain, specialty, orthopedics and urology,” said Rajiv De Silva, President and CEO of Endo. “While we will miss Brian and his contributions, we will continue to build our U.S. Branded business as Endo focuses on accelerating key growth drivers including XIAFLEX® and BELBUCA™. I would especially like to thank Brian for agreeing to remain in his position through the transition phase. We wish him continued success in his future endeavors.”

Under Mr. Lortie’s guidance, Endo’s U.S. Branded business achieved many significant milestones, including:

  • The restructuring of the core U.S. Branded business to mitigate the impact of Lidoderm® loss of exclusivity;
  • The strengthening of the Commercial Operations function to support the growth of Endo’s U.S. Branded business going forward;
  • The successful acquisition of Auxilium, which added XIAFLEX® and its related pipeline to Endo’s U.S. Branded portfolio;
  • The in-licensing and regulatory approval of BELBUCA™ and the subsequent launch of this differentiated product; and
  • The successful extension of the VOLTAREN® Gel licensing agreement, including securing Endo’s rights to an Authorized Generic.

“It has been a pleasure to have been a part of Endo over what have been truly transformational years for the Company and during a time of great change for the U.S. Branded business,” said Mr. Lortie. “I am proud of what we have achieved and now, will work with Rajiv and the Endo team to transition the U.S. Branded business to new leadership and position it for its next phase of growth.”

Source: Endo International plc

comments closed

Related News

March 25, 2023

UK regulator makes biggest changes in 20 years to speed up trials, attract global studies

Life sciences

The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) has introduced several new measures to make it easier to run clinical trials in the country, marking the first time in 20 years the regulatory body has made such an overhaul.

March 25, 2023

Novo partners with Dewpoint to mine an emerging field for new drugs

Life sciences

Diabetes drugmaker Novo Nordisk is partnering with Dewpoint Therapeutics in a deal aimed at uncovering new treatments for insulin resistance by targeting cellular droplets known as biomolecular condensates. Dewpoint will receive $55 million upfront from Novo, which plans to develop small molecule drugs against targets discovered using Dewpoint’s technology.

March 25, 2023

Sanofi’s Dupixent receives EC approval for atopic dermatitis

Life sciences

Sanofi has secured approval for Dupixent (dupilumab) from the European Commission (EC) to treat severe atopic dermatitis in children aged six months to five years, who are systemic therapy candidates, in the European Union (EU). This approval makes Dupixent the first and only medicine available in the US and Europe for the treatment of such young children.

How can we help you?

We're easy to reach